Tradestie Institutional Equity Comparison Engine

CVM vs AGEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AGEN Overall Edge

AGEN Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Agenus Inc. (AGEN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus AGEN at 3.7x Forward P/E and 38.9% operating margin (+4.1% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against AGEN sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
CVM 23.0x vs AGEN 3.7x Fwd P/E
Growth & Margin Winner AGEN
Op Margin 0.0% vs 38.9% ยท YoY -62.7% vs +4.1%
Momentum & Technical Winner AGEN
1Y -77.5% vs +46.4% ยท 52W Pos 10% vs 48%
Options & Structure Winner AGEN
BREAKDOWN (N/A IV) vs BREAKDOWN (11th %ile IV)
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
AGEN NASDAQ
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.34
-5.79% 1D
Market Cap $310.8M
1M Return +4.97%
1Y Return +46.42%
Forward P/E 3.7x
Unified AI Score
51.5 / 100 HOLD
Tech 49.0 Fund 55.0 Flow 66.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CVM -77.48% AGEN +46.42% Spread: +122.06 pp (AGEN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CVM Revenue AGEN Revenue CVM Op. Margin AGEN Op. Margin Margin Edge
FY2018 N/A $40M N/A -336.6% AGEN
FY2019 N/A $150M N/A -46.7% AGEN
FY2020 N/A $90M N/A -133.0% AGEN
FY2021 N/A $300M N/A 8.7% AGEN
FY2022 N/A $100M N/A -183.0% AGEN
FY2023 N/A $160M N/A -102.1% AGEN
FY2024 N/A $100M N/A -116.4% AGEN
FY2025 N/A $110M N/A -17.7% AGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CVM (3) vs AGEN (7)
Institutional Metric CVM AGEN Criterion Row Winner
Market Capitalization Scale $20.9M $310.8M Larger Scale AGEN
Trailing P/E Ratio Valuation 23.0x 29.9x Lower Multiple CVM
Forward P/E Ratio Valuation 23.0x 3.7x Lower Multiple AGEN
Revenue Growth (YoY) Growth -62.7% +4.1% Higher Growth AGEN
Operating Margin (TTM) Profitability 0.0% 38.9% Higher Margin AGEN
Net Profit Margin Profitability 0.0% 30.8% Higher Margin AGEN
Return on Equity (ROE) Capital Efficiency -252.5% -1278.8% Higher ROE CVM
52-Week Range Position Momentum 10% ($1โ€“$8) 48% ($3โ€“$10) Stronger Trend AGEN
Beta / 30D Volatility Risk Regime 0.65ฮฒ ยท 120% Vol 1.60ฮฒ ยท 76% Vol Lower Realized Risk AGEN
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 51.5 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CVM vs AGEN Buy Guide
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AGEN BREAKDOWN
33d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live AGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CVM nor AGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.